Peter Zerhouni has been involved in all aspects of the Company since 2006 and he is since April 2011 Acting President and CEO of the Company. He assumes his position as President and CEO of Diamyd Medical AB on July 4, 2011.
Peter Zerhouni has during the years played a key role in driving the Company’s business and clinical trials forward. He has a combined financial and biotechnology background with degrees in Biology and Economics & Business Administration from Lund University in Sweden and University of California at Berkeley in the USA.
About Diamyd Medical
Diamyd Medical is a Swedish pharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and pain. The Diabetes business area consists of the antigen-based drug candidate Diamyd® for the treatment and prevention of autoimmune diabetes. The Pain business area consists of development projects that use the Company’s proprietary NTDDS (Nerve Targeting Drug Delivery System) platform to administer drugs directly to the nervous system to treat chronic pain. A Phase II study of the candidate drug NP2 Enkephalin for cancer pain is ongoing in the US.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).